{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:17:16Z","timestamp":1784924236079,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10620-012-2140-5","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:33:26Z","timestamp":1332203606000},"page":"2233-2240","source":"Crossref","is-referenced-by-count":132,"title":["Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma"],"prefix":"10.1007","volume":"57","author":[{"given":"David E.","family":"Kleiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"key":"2140_CR1","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275\u20135283.","journal-title":"J Clin Oncol"},{"key":"2140_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2\u20139.","journal-title":"Oncologist"},{"key":"2140_CR3","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591\u20135598.","journal-title":"Clin Cancer Res"},{"key":"2140_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155\u2013164.","journal-title":"Lancet Oncol"},{"key":"2140_CR5","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm phase II study. Ann Oncol. 2010;21:1712\u20131717.","journal-title":"Ann Oncol"},{"key":"2140_CR6","unstructured":"Maio M, Lebb\u00e9 C, Neyns B, et al. Three-Year Survival Rates for Patients with Advanced Melanoma Who Received Ipilimumab at 10\u00a0mg\/kg in Phase II Trials [Abstract]. In: Presented at the XIV annual meeting of the perspectives in melanoma, 2010 September 17\u201318, Amsterdam, The Netherlands. 2010."},{"key":"2140_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u2013723.","journal-title":"N Engl J Med"},{"key":"2140_CR8","doi-asserted-by":"crossref","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u20132526. doi: 10.1056\/NEJMoa1104621 .","DOI":"10.1056\/NEJMoa1104621"},{"key":"2140_CR9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864\u2013872.","journal-title":"Oncologist"},{"key":"2140_CR10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","volume":"37","author":"A Hoos","year":"2010","unstructured":"Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533\u2013546.","journal-title":"Semin Oncol"},{"key":"2140_CR11","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockades in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372\u20138377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2140_CR12","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043\u20136053.","journal-title":"J Clin Oncol"},{"key":"2140_CR13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2010.06.032","volume":"54","author":"D Qiu","year":"2011","unstructured":"Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011;54:340\u2013347.","journal-title":"J Hepatol"},{"key":"2140_CR14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver Injury. Clin Pharmacol Ther. 2011;89:806\u2013815.","journal-title":"Clin Pharmacol Ther"},{"key":"2140_CR15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958\u2013976.","journal-title":"Dig Dis Sci"},{"key":"2140_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.semdp.2006.11.001","volume":"23","author":"AA Suriawinata","year":"2006","unstructured":"Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol. 2006;23:132\u2013148.","journal-title":"Semin Diagn Pathol"},{"key":"2140_CR17","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","volume":"360","author":"MR Lucey","year":"2009","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758\u20132769.","journal-title":"N Engl J Med"},{"key":"2140_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","volume":"354","author":"EL Krawitt","year":"2006","unstructured":"Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54\u201366.","journal-title":"N Engl J Med"},{"key":"2140_CR19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931\u2013939.","journal-title":"Hepatology"},{"key":"2140_CR20","first-page":"11","volume":"10","author":"D Berman","year":"2010","unstructured":"Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11\u201321.","journal-title":"Cancer Immun"},{"key":"2140_CR21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1024\/0040-5930\/a000149","volume":"68","author":"MC Sulz","year":"2011","unstructured":"Sulz MC, Gerlach TJ. Autoimmune hepatitis. Ther Umsch. 2011;68:189\u2013194.","journal-title":"Ther Umsch"},{"key":"2140_CR22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u2013699.","journal-title":"J Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2140-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2140-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:44:59Z","timestamp":1559231099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2140-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,21]]}}}